BidaskClub upgraded shares of FibroGen (NASDAQ:FGEN) from a sell rating to a hold rating in a report issued on Thursday.

Other analysts also recently issued reports about the stock. Stifel Nicolaus reissued a buy rating and set a $80.00 price objective on shares of FibroGen in a research report on Thursday, September 14th. Jefferies Group reissued a buy rating and set a $75.00 price objective on shares of FibroGen in a research report on Tuesday, September 12th. Mizuho reissued a hold rating and set a $61.00 price objective on shares of FibroGen in a research report on Thursday, November 9th. Finally, ValuEngine downgraded shares of FibroGen from a hold rating to a sell rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. FibroGen currently has an average rating of Buy and a consensus price target of $65.67.

Shares of FibroGen (NASDAQ:FGEN) traded up $2.25 during mid-day trading on Thursday, reaching $47.80. 569,171 shares of the company traded hands, compared to its average volume of 632,113. FibroGen has a one year low of $19.55 and a one year high of $60.15. The stock has a market cap of $3,744.09, a P/E ratio of -23.43 and a beta of 1.56. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16.

In other news, Director Thomas F. Kearns, Jr. sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $45.22, for a total transaction of $813,960.00. Following the sale, the director now owns 156,564 shares of the company’s stock, valued at approximately $7,079,824.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gerald Lema purchased 3,500 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were bought at an average cost of $46.70 per share, for a total transaction of $163,450.00. Following the acquisition, the director now owns 3,500 shares in the company, valued at $163,450. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 346,346 shares of company stock worth $17,855,633. Insiders own 13.60% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC boosted its holdings in shares of FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after buying an additional 1,641,423 shares during the last quarter. EcoR1 Capital LLC boosted its holdings in shares of FibroGen by 3,674.1% in the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock worth $51,210,000 after buying an additional 1,543,448 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of FibroGen in the second quarter worth approximately $45,633,000. Eagle Asset Management Inc. purchased a new position in shares of FibroGen in the third quarter worth approximately $46,158,000. Finally, Vanguard Group Inc. boosted its holdings in shares of FibroGen by 15.1% in the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after buying an additional 761,421 shares during the last quarter. 57.37% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “FibroGen (FGEN) Lifted to Hold at BidaskClub” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/12/24/fibrogen-fgen-lifted-to-hold-at-bidaskclub-2.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with Analyst Ratings Network's FREE daily email newsletter.